Co-expression and prognostic significance of the HER family members, EGFRvIII, c-MET, CD44 in patients with ovarian cancer

EGFR and HER-2 are important targets but none of the monoclonal antibodies or small molecule tyrosine kinase inhibitors specific for the HER members has been approved for the treatment of patients with ovarian cancers. In some studies, co-expression of other growth factor receptors has been associat...

Descripción completa

Detalles Bibliográficos
Autores principales: Puvanenthiran, Soozana, Essapen, Sharadah, Haagsma, Ben, Bagwan, Izhar, Green, Margaret, Khelwatty, Said Abdullah, Seddon, Alan, Modjtahedi, Helmout
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5929416/
https://www.ncbi.nlm.nih.gov/pubmed/29731973
http://dx.doi.org/10.18632/oncotarget.24791

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5929416/
https://www.ncbi.nlm.nih.gov/pubmed/29731973
http://dx.doi.org/10.18632/oncotarget.24791

Ejemplares similares